OBJECTIVE: Although the role of regulatory B cells (Bregs) in rheumatic disease has gained increasing attention, two lesser-known Breg subsets that express either Foxp3 or transforming growth factor beta (TGFβ) are rarely examined in studies of rheumatic disease. This study investigates the association between the relative proportions of CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs, and clinical indicators of disease severity in rheumatoid arthritis (RA) patients with or without interstitial lung disease (ILD). METHODS: A total of 31 RA patients (14 with and 17 without ILD) and 26 healthy control subjects were included. All subjects did not have other autoimmune disease except RA, tumor, active infection, or a history of related drug administration. Peripheral blood mononuclear cells (PBMCs) were isolated and analyzed by flow cytometry (FCM). The relationship between the relative proportions of CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs and their associations to RA and ILD incidence, as well as disease severity assessed by common clinical indicators, were then examined. RESULTS: Our analyses revealed RA patients had significantly lower proportions of peripheral CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs as compared to healthy controls. While no association was observed between CD19(+)Foxp3(+) Bregs and ILD incidence, patients with ILD had a substantially lower percentage of CD19(+)TGFβ(+) Bregs compared to RA patients without ILD. In addition, CD19(+)Foxp3(+) Bregs were negatively correlated with erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in RA patients, whereas CD19(+)TGFβ(+) Bregs were only correlated with CRP in RA patients with ILD. Furthermore, there was a negative association between CD19(+)Foxp3(+) Bregs and disease severity scores, which was not found in analyses with CD19(+)TGFβ(+) Bregs. CONCLUSIONS: The proportions CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs were significantly decreased in RA patients, particularly in those with ILD complications, suggesting that Breg phenotypes may have different functions in the pathogenesis of RA and ILD.
OBJECTIVE: Although the role of regulatory B cells (Bregs) in rheumatic disease has gained increasing attention, two lesser-known Breg subsets that express either Foxp3 or transforming growth factor beta (TGFβ) are rarely examined in studies of rheumatic disease. This study investigates the association between the relative proportions of CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs, and clinical indicators of disease severity in rheumatoid arthritis (RA) patients with or without interstitial lung disease (ILD). METHODS: A total of 31 RApatients (14 with and 17 without ILD) and 26 healthy control subjects were included. All subjects did not have other autoimmune disease except RA, tumor, active infection, or a history of related drug administration. Peripheral blood mononuclear cells (PBMCs) were isolated and analyzed by flow cytometry (FCM). The relationship between the relative proportions of CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs and their associations to RA and ILD incidence, as well as disease severity assessed by common clinical indicators, were then examined. RESULTS: Our analyses revealed RApatients had significantly lower proportions of peripheral CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs as compared to healthy controls. While no association was observed between CD19(+)Foxp3(+) Bregs and ILD incidence, patients with ILD had a substantially lower percentage of CD19(+)TGFβ(+) Bregs compared to RApatients without ILD. In addition, CD19(+)Foxp3(+) Bregs were negatively correlated with erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in RApatients, whereas CD19(+)TGFβ(+) Bregs were only correlated with CRP in RApatients with ILD. Furthermore, there was a negative association between CD19(+)Foxp3(+) Bregs and disease severity scores, which was not found in analyses with CD19(+)TGFβ(+) Bregs. CONCLUSIONS: The proportions CD19(+)Foxp3(+) and CD19(+)TGFβ(+) Bregs were significantly decreased in RApatients, particularly in those with ILD complications, suggesting that Breg phenotypes may have different functions in the pathogenesis of RA and ILD.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Jamie G Evans; Karina A Chavez-Rueda; Ayad Eddaoudi; Almut Meyer-Bahlburg; David J Rawlings; Michael R Ehrenstein; Claudia Mauri Journal: J Immunol Date: 2007-06-15 Impact factor: 5.422
Authors: Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope Journal: Arthritis Rheum Date: 2013-10-03
Authors: Tineke Cantaert; Marieke E Doorenspleet; Gabriela Francosalinas; Jaqueline E Paramarta; Paul L Klarenbeek; Yvonne Tiersma; Chris M van der Loos; Niek De Vries; Paul Peter Tak; Dominique L Baeten Journal: Arthritis Rheum Date: 2012-01-09
Authors: B Wilde; M Thewissen; J Damoiseaux; S Knippenberg; M Hilhorst; P van Paassen; O Witzke; J W Cohen Tervaert Journal: Ann Rheum Dis Date: 2013-05-10 Impact factor: 19.103
Authors: P Natarajan; A Singh; J T McNamara; E R Secor; L A Guernsey; R S Thrall; C M Schramm Journal: Mucosal Immunol Date: 2012-06-20 Impact factor: 7.313
Authors: Diego Catalán; Miguel Andrés Mansilla; Ashley Ferrier; Lilian Soto; Kristine Oleinika; Juan Carlos Aguillón; Octavio Aravena Journal: Front Immunol Date: 2021-04-29 Impact factor: 7.561
Authors: Kristbjörg Bjarnadóttir; Mahdia Benkhoucha; Doron Merkler; Martin S Weber; Natalie L Payne; Claude C A Bernard; Nicolas Molnarfi; Patrice H Lalive Journal: Sci Rep Date: 2016-10-06 Impact factor: 4.379